If you are wondering whether CorMedix is starting to look mispriced after a rough stretch, this article walks through what the current share price might imply about its underlying value.
The stock closed at US$7.09, with returns of a 36.5% decline over 7 days, a 37.4% decline over 30 days and a 41.7% decline year to date, set against a 60.8% gain over 3 years and a 19.8% decline over 5 years.
Recent CorMedix headlines have focused on its progress and risks as a smaller pharmaceuticals and biotech player, giving context to why sentiment can swing quickly around key company updates. These shifts in attention can help explain why short term returns look very different from the longer term picture.
